Ghana made history on Tuesday, October 7, 2025, by introducing the Human Papillomavirus (HPV) vaccine into its national ...
Human papillomavirus vaccination reached 82.1% by 2023, lowering rates among both unvaccinated and vaccinated individuals.
The U.S. Human Papilloma Virus (HPV) testing market is poised for significant growth, projected to reach $1.01 billion by ...
Cervical cancer remains one of the most preventable yet deadly cancers for women worldwide, with vast disparities between high-income nations and ...
DeepSeek, a blood test that can detect HPV-linked head and neck cancers nearly a decade before diagnosis. By finding viral DNA in the bloodstream, the test achieved 99% sensitivity and specificity.
Boston, USA-based Bicara Therapeutics, a biotech focused on developing bifunctional therapies for solid tumors, announced ...
Ficerafusp alfa is currently being evaluated in FORTIFI-HN01, a pivotal Phase 2/3 clinical trial in patients with first line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma ...
Mass General Brigham’s HPV-DeepSeek test enables much earlier cancer detection through a blood sample, creating a new ...
A large, long-term study led by an Albert Einstein College of Medicine researcher has found that the introduction of the ...
New research published in JAMA Network Open finds that mailing human papillomavirus (HPV) self-sampling kits to patients is a ...
A large, long-term study led by an Albert Einstein College of Medicine researcher has found that the introduction of the ...